fda compounding semaglutide crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns on Certain Forms
Description
The funders had no role in the design of the study
have flattened in the last few months
Additionally, one study reported increased dysgeusia (loss of taste), throat tightness and irritation, dysphagia (difficulty swallowing), and dysphonia (difficulty speaking) ( Khan et al
lipid panels are paired with hepatic enzymes and indices of de novo lipogenesis
After struggling to adapt to newer diets and weight-loss medications, as well as facing $1.5 billion in debt, the company has made a major comeback
